CUE

Cue Biopharma, Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$17.5

Price (1 Year)

$37.05 $5.4

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %1.3 / %30
Non-compliant assets / Total market cap %0 / %30
Non-compliant revenue / Total income %2.4 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.

Website

Analysis (Turkish): CUE Hissesi Caiz mi, Helal mi? Cue Biopharma, Inc. Katılım Analizi